Jeong Hee Beom, Kim Yong-Il, Yoon Soyoon, Lee Dong Yun, Kim Beom-Jun, Lee Seung Hun, Ryu Jin-Sook
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Nucl Med Mol Imaging. 2025 Feb;59(1):72-78. doi: 10.1007/s13139-024-00878-x. Epub 2024 Aug 22.
C-Methionine PET/CT is a promising method for detecting parathyroid lesions in patients with primary hyperparathyroidism (PHPT). We aimed to determine the diagnostic ability and correlation of digital C-Methionine PET/CT for parathyroid lesions in patients with PHPT, particularly in cases where standard imaging methods yielded inconclusive results.
This retrospective analysis was conducted on patients diagnosed with PHPT who underwent digital C-Methionine PET/CT imaging because of ambiguous results on standard imaging work-up (Tc-MIBI parathyroid scan and/or neck ultrasonography). Quantitative C-Methionine PET/CT parameters, including maximum standardized uptake value (SUVmax), mean SUV (SUVmean), peak SUV (SUVpeak), parathyroid methionine volume (PMV), and whole methionine uptake (WMU: PMV multiplied by SUVmean) were calculated with various thresholds, and their correlations with biochemical and pathologic parameters were investigated.
This study included 22 consecutive patients (10 men and 12 women) with a median age of 64.0 years. The lesion detection rate and sensitivity of digital C-Methionine PET/CT were 81.8% (18/22) and 100.0% (18/18), respectively. Quantitative analysis revealed that serum PTH ( = 0.490, = 0.039) and serum calcium ( = 0.583, = 0.011) were significantly correlated with PMV50%.
Digital C-Methionine PET/CT offers good performance in the detection of parathyroid lesions in PHPT patients with inconclusive standard imaging work-up. The volume parameter of PMV50% significantly correlated biochemical parameters and can serve as a complementary diagnostic tool.
The online version contains supplementary material available at 10.1007/s13139-024-00878-x.
¹¹C-蛋氨酸PET/CT是检测原发性甲状旁腺功能亢进症(PHPT)患者甲状旁腺病变的一种有前景的方法。我们旨在确定¹¹C-蛋氨酸数字PET/CT对PHPT患者甲状旁腺病变的诊断能力及相关性,尤其是在标准成像方法结果不明确的情况下。
对因标准成像检查(锝-99m甲氧基异丁基异腈甲状旁腺扫描和/或颈部超声)结果不明确而接受¹¹C-蛋氨酸数字PET/CT成像的PHPT患者进行回顾性分析。计算¹¹C-蛋氨酸PET/CT的定量参数,包括最大标准化摄取值(SUVmax)、平均SUV(SUVmean)、峰值SUV(SUVpeak)、甲状旁腺蛋氨酸体积(PMV)和全蛋氨酸摄取量(WMU:PMV乘以SUVmean),采用不同阈值,并研究它们与生化和病理参数的相关性。
本研究纳入22例连续患者(10例男性和12例女性),中位年龄64.0岁。¹¹C-蛋氨酸数字PET/CT的病变检出率和灵敏度分别为81.8%(18/22)和100.0%(18/18)。定量分析显示,血清甲状旁腺激素(r = 0.490,P = 0.039)和血清钙(r = 0.583,P = 0.011)与PMV50%显著相关。
¹¹C-蛋氨酸数字PET/CT在标准成像检查结果不明确的PHPT患者甲状旁腺病变检测中表现良好。PMV50%的体积参数与生化参数显著相关,可作为一种补充诊断工具。
在线版本包含可在10.1007/s13139-024-00878-x获取的补充材料。